ExodusPoint Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

ExodusPoint Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-57,934	Closed	-$430K	–	1687
2023 Q2	$430K	Sell	57,934 -2,343	-4%	-$19.9K	﹤0.01%	1412
2023 Q1	$570K	Buy	60,277 +13,930	+30%	+$147K	﹤0.01%	1302
2022 Q4	$494K	Buy	+46,347	New	+$470K	0.01%	1178
2021 Q4	–	Sell	-17,800	Closed	-$158K	–	2149
2021 Q3	$158K	Buy	+17,800	New	+$124K	﹤0.01%	1828
2021 Q1	–	Sell	-11,900	Closed	-$93K	–	2106
2020 Q4	$93K	Buy	+11,900	New	+$129K	﹤0.01%	1836

Other funds holding ATNM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

ExodusPoint Capital Management's ATNM Position: Q3 2023 in Review

ExodusPoint Capital Management sold out of Actinium Pharmaceuticals (ATNM) in Q3 2023, closing a stake of 57,934 shares — an estimated $430K sold.

ExodusPoint Capital Management first reported a position in ATNM in Q4 2020 and held it in 5 quarters. The position peaked at $570K in Q1 2023. 58 funds tracked by Wall St. Rank hold ATNM as of Q3 2023.

ExodusPoint Capital Management reported no remaining Actinium Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
ExodusPoint Capital Management sold 57,934 Actinium Pharmaceuticals shares in Q3 2023, an estimated $430K.
ExodusPoint Capital Management first reported a position in Actinium Pharmaceuticals in Q4 2020 and held it in 5 quarters.
ExodusPoint Capital Management's Actinium Pharmaceuticals position peaked at $570K in Q1 2023.
58 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2023.

Based on ExodusPoint Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.